We are proposing to have a central Cell CORE for expanding, cryopreserving, and distributing tumor and vaccine cells that will be utilized by alt 4 projects in this NCDDG program. The main purpose of this CORE is to provide standardized reagents to all 4 projects in the NCDDG program. This will allow for comparative studies since cell lines will be used at equivalent passages, and will have undergone regular stability testing. The in vivo feasibility and optimization data obtained using these Core generated reagents will be suitable for including in investigator-initiated INDs submitted to support the clinical trials that arise from this NCDDG program. Cell banks for vaccine cell lines and tumor lines (mouse and human) will be produced under standard operating procedures, cryopreserved, and distributed to investigators in the program as needed. Quality control assays will be established for each banked reagent and performed on the expanded bank of reagents to insure the stability of the reagent has been maintained. Dr. Jaffee will be the CORE leader. The CORE will be responsible for distributing the reagents upon request from an investigator. The CORE will also be responsible for emonstrating stability of the reagents. Individual investigators will be responsible for limited expansion of the cell lines received from the CORE that are used in a particular experiment. There are four specific aims of this CORE.
Specific aim #1. Produce, cryopreserve, and distribute to investigators, Master Cell Banks (MCB) of individual cell lines.
Specific aim #2. Perform quality control assays on the pre-expansion and post-expansion (MCB) cell lines.
Specific aim #3. Perform yearly stability testing of MCB cell lines.
Specific aim #4. Distribute cell lines to all four investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19CA113341-02
Application #
7311294
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2006-05-01
Budget End
2007-04-30
Support Year
2
Fiscal Year
2006
Total Cost
$65,478
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Keenan, Bridget P; Saenger, Yvonne; Kafrouni, Michel I et al. (2014) A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 146:1784-94.e6
Yao, Sheng; Zhu, Yuwen; Chen, Lieping (2013) Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 12:130-46
Zhu, Yuwen; Yao, Sheng; Iliopoulou, Bettina P et al. (2013) B7-H5 costimulates human T cells via CD28H. Nat Commun 4:2043
Yao, Sheng; Zhu, Yuwen; Zhu, Gefeng et al. (2011) B7-h2 is a costimulatory ligand for CD28 in human. Immunity 34:729-40
Uram, Jennifer N; Black, Chelsea M; Flynn, Emilee et al. (2011) Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response. J Immunol 186:3847-57
Zhang, Yu-Qian; Tsai, Ya-Chea; Monie, Archana et al. (2010) Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther 18:692-9
Mao, Chih-Ping; Wu, T-C (2010) Inhibitory RNA molecules in immunotherapy for cancer. Methods Mol Biol 623:325-39
Kim, Daejin; Hoory, Talia; Monie, Archana et al. (2010) Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors. J Biomed Sci 17:61
Pfannenstiel, Lukas W; Lam, Samuel S K; Emens, Leisha A et al. (2010) Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol 263:79-87
Yi, Kyung H; Chen, Lieping (2009) Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev 229:145-51

Showing the most recent 10 out of 34 publications